SOLICITATION DOCUMENT Sample Clauses

SOLICITATION DOCUMENT. Exempt-Government Entity SECTION IV.
Sample 1
AutoNDA by SimpleDocs
SOLICITATION DOCUMENT. A document developed by the County to obtain bids, proposals, and other information from bidders/proposers.
Sample 1
SOLICITATION DOCUMENT. Exempt - Governmental Entity J. All invoices will reference the Purchase Order Number. A. Funding from The United States Health and Humans Services (HHS) and the Substance Abuse and Mental Health Services Administration (SAMHSA) fund the HHSC Substance Use Disorder project(s), which includes this contract. B. This contract is funded with the Catalog of Federal Domestic Assistance (CFDA) funds, Texas Targeted Opioid Response (TTOR) State Targeted Response (STR) and State Opioid Response (SOR) grants, CFDA 93.788 C. The total reimbursements for the contract are as follows: 1. In Fiscal Year 2020, the total reimbursements will not exceed $4,515,660.00, for the term September 1, 2019 through September 29, 2020. The funding is allocated as follows: a. TTOR STR grant allocation is $3,010,440.00, for the term September 1, 2019 through April 30, 2020: b. TTOR SOR grant allocation is $1,505,220.00, for the term May 1, 2020 through August 31, 2020. 2. In Fiscal Year 2021, the total reimbursements will not exceed $376,305.00, for the term September 1, 2020 through September 29, 2020. The funding is allocated from the TTOR SOR grant funds. a. TTOR SOR grant allocation is $326,502.00, for the term September 1, 2020 through September 29, 2020. D. Performing Agency Share (Match) TTOR grant funds do not require match. E. Performing Agency will submit invoices to the System Agency through the Clinical Management for Behavioral Health Services (CMBHS) system monthly. F. Any unexpended balance associated with any other System Agency Contract may not be applied to this System Agency Contract. G. System Agency funded capacity is defined as the stated number of clients that will be concurrently served as determined by this Contract. H. Clinic Numbers must be approved by the Assigned Contract Manager before billing can occur. Clinic Change Request form is located at: xxxx://xxx.xxxx.xxxxx.xxx/sa/For- I. Service Types with no associated Amount will be paid from the preceding Service Type with an associated Amount.
Sample 1
SOLICITATION DOCUMENT. Exempt - Governmental Entity N. All invoices will reference the Purchase Order Number. A. TREATMENT CONSIDERATIONS The medical literature supports the use of opioid substitution therapy as first-line treatment for patients with opioid use disorders. Substance Abuse and Mental Health Services Administration (SAMHSA), American Society of Addiction Medicine (ASAM) and the Veterans Administration (VA) indicate that extended-release injectable naltrexone may be an acceptable alternative to opioid substitution therapy in selected patients. Careful patient selection is essential in order to maximize the chance of long-term treatment success and to minimize the risk of adverse outcomes including relapse and overdose. Several organizations, including SAMHSAi, VAii, ASAMiii and Providers’ Clinical Support System for Medication Assisted Treatment (PCSS-MAT)iv have published guidance on which patients may be the best candidates for treatment with extended-release injectable naltrexone. Patient selection criteria based on that guidance and on a review of the other available literature are included below. These criteria are intended as guidelines and should not be considered a substitute for the clinical judgment of the treating physician. The optimal duration of treatment with extended-release injectable naltrexone has not been determined. Most studies have been based on 6 months of medication, but data on long-term outcomes is lacking. The decision to discontinue medication must be determined on a case-by- case basis and in conjunction with patient preference, taking into account the relative risks and benefits. As with other forms of medication-assisted treatment (MAT), extended-release injectable naltrexone must only be used as part of a comprehensive program of treatment that includes counseling and behavioral therapy. Patients should be encouraged to participate in recovery- related activities in addition to formal counseling. B. PHYSICIAN EDUCATION REQUIREMENTS Prior to initiation of treatment with extended-release injectable naltrexone, the ordering physician must gain a thorough understanding of the use of this medication in the treatment of patients with opioid use disorder. The treating physician must: 1. Become familiar with the published guidelines for the use of this medication, such as those by XXXXXX, ASAM and the VA; 2. Become familiar with and follow the Food & Drug Administration (FDA) prescribing information, REMS and manufacturer’s recommendations r...
Sample 1
SOLICITATION DOCUMENT. Proprietary/Sole Source purchase.
Sample 1
SOLICITATION DOCUMENT. The Department of State Health Services (DSHS) Substance Abuse Intervention Programs Request for Proposals issued on November 5, 2012, RFP# SA/INTV-540.1. None
Sample 1

Related to SOLICITATION DOCUMENT

  • Non-Solicitation Agreement Executive agrees and covenants that he will not, unless acting with the Company’s express written consent, directly or indirectly, during the Term of this Agreement or during the Non-Competition Period (as defined in Section 11 above) solicit, entice or attempt to entice away or interfere in any manner with the Company’s relationships or proposed relationships with any customer, officer, employee, consultant, proposed customer, vendor, supplier, proposed vendor or supplier or person or entity or person providing or proposed to provide research and/or development services to, on behalf of or with the Company.

  • Solicitation The Company will provide each holder of the Notes (irrespective of the amount of Notes then owned by it) with sufficient information, sufficiently far in advance of the date a decision is required, to enable such holder to make an informed and considered decision with respect to any proposed amendment, waiver or consent in respect of any of the provisions hereof or of the Notes. The Company will deliver executed or true and correct copies of each amendment, waiver or consent effected pursuant to the provisions of this Section 17 to each holder of outstanding Notes promptly following the date on which it is executed and delivered by, or receives the consent or approval of, the requisite holders of Notes.

  • Non-Competition/Solicitation To the Company’s knowledge, no Respondent is subject to any non-competition agreement or non-solicitation agreement with any employer or prior employer which could materially affect such Respondent’s ability to be and act in the capacity of a director or officer of the Company, as applicable.

  • Non-Solicitation While employed and for the one-year period starting on the date of Termination of Employment, any Participant who has received an Award under the Plan shall not, directly or indirectly: (i) other than in connection with the good-faith performance of his or her normal duties and responsibilities as an employee of the Company or any Subsidiary, encourage any employee or agent of the Company or any Subsidiary to terminate his or her relationship with the Company or any Subsidiary; (ii) employ, engage as a consultant or adviser, or solicit the employment or engagement as a consultant or adviser of, any employee or agent of the Company or Subsidiary (other than by the Company or its Subsidiaries), or cause or encourage any Person to do any of the foregoing; (iii) establish (or take preliminary steps to establish) a business with, or encourage others to establish (or take preliminary steps to establish) a business with, any employee or exclusive agent independent contractor of the Company or its Subsidiaries that would interfere with the relationship between the Company or its Subsidiaries and the employee or agent; or (iv) interfere with the relationship of the Company or its Subsidiaries with, or endeavor to entice away from the Company or its Subsidiaries, any Person who or which at any time since the Participant's hire date was or is a material customer or material supplier of, or maintained a material business relationship with, the Company or its Subsidiaries. If a Participant violates any of the non-solicitation provisions set forth above, to the extent permitted by applicable law, the Board or the Committee may, to the extent permitted by applicable law, (i) cancel or cause to be cancelled any or all of the Participant's outstanding Awards granted after May 19, 2009; (ii) recover or cause to be recovered any or all Proceeds resulting from any sale or other disposition (including to the Company) of shares of Stock issued or issuable upon vesting, settlement, or exercise, as the case may be, of any Award granted after May 19, 2009, if the sale or disposition was effected on or after the date that is one year prior to the date on which the Participant first violated any such non-solicitation provisions; and/or (iii) recover or cause to be recovered any cash paid or shares of Stock issued to the Participant in connection with any vesting, settlement, or exercise of an Award granted after May 19, 2009, if the vesting, settlement, or exercise occurred on or after the date that is one year prior to the date on which the Participant first violated any such the non-solicitation provisions.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!